Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company has multiple core pipeline catalysts, with KN026 having submitted a listing application and expected to be approved by the end of 2026 or early 2027. The product is a HER2 bispecific monoclonal antibody targeting gastric cancer and breast cancer [7][12] - JSKN003, the company's first ADC pipeline, is progressing rapidly with promising clinical data for ovarian and colorectal cancers, with an NDA application expected in 2026 [21][24] - The self-developed platform continues to yield new ADC molecules entering clinical stages, including JSKN022 and JSKN027, which are expected to start clinical trials in 2026 [27][29] - Revenue forecasts for 2025-2026 are maintained at 4.14 billion and 4.71 billion CNY, respectively, with a new forecast for 2027 at 5.63 billion CNY. The net profit forecasts for 2025-2026 are adjusted to -1.15 billion and -0.97 billion CNY, respectively, with a new forecast for 2027 at -0.26 billion CNY [1][30] Summary by Sections Core Pipeline Developments - KN026 has been accepted for review by the NMPA for gastric cancer treatment, with further applications for breast cancer expected in 2026 [12][13] - JSKN003 is advancing in clinical trials for HER2-positive breast cancer, with significant efficacy data reported for ovarian and colorectal cancers [21][24] Self-Developed Platform - The company is leveraging its antibody development technology to expand its ADC pipeline, with several new candidates expected to enter clinical trials soon [27][29] Financial Projections - The report maintains revenue projections for 2025-2026 at 4.14 billion and 4.71 billion CNY, with a new forecast for 2027 at 5.63 billion CNY. Adjustments to net profit forecasts reflect increased R&D expenses, with expected losses narrowing as products approach market approval [1][30]
康宁杰瑞制药-B（09966）：核心管线上市申报中，新分子即将进入临床